Phentolamine
- Generic Name
- Phentolamine
- Brand Names
- Oraverse
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O
- CAS Number
- 50-60-2
- Unique Ingredient Identifier
- Z468598HBV
- Background
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine. It has several therapeutic uses, includi...
- Indication
1.用于预防和治疗嗜铬细胞瘤所致的高血压发作，包括手术切除时出现的阵发性高血压，也可根据血压对本品的反应用于协助诊断嗜铬细胞瘤；
2.治疗左心衰竭；
3.治疗去甲肾上腺素、去氧肾上腺素、间羟胺等静脉给药外溢，用于防止皮肤坏死；
4.临床还用于治疗男性勃起功能障碍（ED）。最新研究表明，本品与罂粟碱、前列地尔三联用药，可降低引起平滑肌收缩的交感神经张力，使阴茎动脉平滑肌松弛，增加阴茎动脉血流，有利勃起。
- Associated Conditions
- Mydriasis, Necrosis caused by norepinephrine extravasation, Pheochromocytoma, Sloughing Skin, Soft Tissue Anesthesia (Numbness), Hypertensive episodes
- Associated Therapies
- -
Pre-operative Phentolamine Vs Intraoperative Esmolol Efficacy for Hypotensive Anesthesia in Functional Endoscopic Sinus Surgery
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT06620991
- Locations
- 🇪🇬
Ain Shams University, Cairo, Egypt
The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II
- Conditions
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT06422494
Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 200
- Registration Number
- NCT06385600
Efficacy of Phentolamine in Prevention of Contrast-Associated Acute Kidney Injury After Complex PCI
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Helwan University
- Target Recruit Count
- 60
- Registration Number
- NCT06286059
- Locations
- 🇪🇬
Badr university hospital, Badr, Cairo, Egypt
Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Children
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 80
- Registration Number
- NCT05448807
Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity
- Conditions
- Interventions
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 104
- Registration Number
- NCT04436731
- Locations
- 🇺🇸
University of Missouri-Columbia, Columbia, Missouri, United States
Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity
- Conditions
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT03318094
- Locations
- 🇺🇸
Autonomic Dysfunction Center, Nashville, Tennessee, United States
Adrenergic System in Islet Transplantation
- Conditions
- Interventions
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 11
- Registration Number
- NCT03079921
- Locations
- 🇺🇸
University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism, Philadelphia, Pennsylvania, United States
Reversing the Effects of 0.5% Bupivacaine
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Dalhousie University
- Target Recruit Count
- 44
- Registration Number
- NCT02995291
- Locations
- 🇨🇦
Dalhousie University Faculty of Dentistry, Halifax, Nova Scotia, Canada
Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients
- Conditions
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Novocol Pharmaceutical of Canada, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01474382
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Indiana University School of Dentistry, Indianapolis, Indiana, United States
🇺🇸University of Pennsylvania School of Dental, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.